Currently, at NeoVentures, we believe that there is no concrete answer to the question if aptamers are better than antibodies. We have thoughts on why aptamers would be more useful in specific cases, but there just isn’t the same amount of literature available yet on… Read More »Are Aptamers Better than Antibodies?
Aptamers are selected from large libraries of random sequences, thus aptamers themselves are not designed but the libraries that they are selected from are. The standard method of aptamer design has been for SELEX selection. This involves a synthetic library with a random region flanked… Read More »Aptamer Libraries – What is Neomers?
We thought that the World Cup was a timely icon for this blog series. This will be a blog series because there are so many reasons why we are the best aptamer company. What are they? You own the aptamers, no royalties. Innovative NEOMER aptamer… Read More »Why is NeoVentures the Best Aptamer Company for Your Needs?
What determines the binding capacity of an aptamer? Our poll results indicate that……… Nature of the target The peptide bond Nucleotide staking free energy Van der Waals forces Let’s go through the options one by one to determine the correct answer. b) The Peptide Bond. It… Read More »What Determines the Binding Capacity of an Aptamer?
Antibody Binding vs. Aptamer Binding The immune system has developed very effective screening methods for eliminating antibodies that bind even weakly to self targets such as serum albumin and IgG. Aptamer selection is done outside the body, on the bench which provides many advantages but implicit… Read More »How We Avoid Self-Recognition with Aptamers
Did you see our poll on LinkedIn? If not, check it out here! Our answer to this poll will be short and sweet: Sugars are molecules that have a generic formula of CnH2nOn. They can be described as polyhydroxy compounds containing one ether bond. Most… Read More »Can Aptamers Bind to Sugar Molecules?
I was just in Leipzig for the in-person portion of BIO-Europe 2022 that ran from October 24th to 26th. It is great to be back in person at BIO-Europe, the last event I was able to attend was in Hamburg in 2019. There were more… Read More »BIO-Europe 2022
The use of the traditional SELEX method for aptamer development has led to the identification of aptamers that bind to a wide diversity of targets. However, there has been limited success with aptamers in therapeutic and diagnostic applications. A key advantage of aptamer development over… Read More »Announcing The Future of Aptamers: Neomers
The clear winner of our poll on antibody specificity was that antibodies have evolved to ignore HAS/IgG. I struggle with this, as I think it is too simple. Really, the way that antibodies rearrange to detect foreign antigens is open; there are no barriers to… Read More »Why Do Antibodies Perform Better in Matrices than Aptamers?
The aptamer market has been growing steadily as there has been increasing awareness of the advantages of aptamers in diagnostic and therapeutic platforms. It has been reported that the global aptamer marker has been forecasted to at least double in value over the next 5… Read More »The Aptamer Market
Subscribe to be the first to know about the latest developments and innovations in commercial aptamers